Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug aims to fix Immunotherapy's blood problems in lung cancer

NCT ID NCT07303881

Not yet recruiting Disease control Sponsor: The First Affiliated Hospital of Guangzhou Medical University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests the drug golidocitinib in 16 people with advanced lung cancer who have severe blood problems caused by immunotherapy. The goal is to see if the drug can safely improve blood counts and reduce symptoms. Participants take the drug until their blood levels recover, for up to 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
golidocitinib
What this could lead to
If successful, this could offer a new treatment option for lung cancer patients who develop severe blood problems from immunotherapy, helping them recover without stopping cancer treatment.
What could go wrong
This is a very small, early-phase trial with only 16 participants, so results may not apply to everyone. The drug may not work or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGIC DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematologic disorder immune reconstitution inflammatory syndrome lung cancer lung neoplasm Neoplasm Metastasis non-small cell lung carcinoma small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOLOGIC DISORDER IRAE LUNG CANCER (LOCALLY ADVANCED OR METASTATIC)

Contacts and locations

Locations

  • First Affiliated Hospital of Guangzhou Medical College

    Guangzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.